Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA;Hartmut Jaeschke, PhD, ATS, FAASLD, is University Distinguished Professor and Past Chairman (2012-2024) of the Department of Pharmacology, Toxicology, and Therapeutics at the University of Kansas Medical Center, Kansas City, Kansas. He is a Fellow of the Academy of Toxicological Sciences (ATS) and Fellow of the American Association for the Study of Liver Diseases (FAASLD). He was the recipient of the Translational Impact Award of the Society of Toxicology (2019) and the Career Achievement Awards of the Mechanisms (2023) and the Clinical and Translational Toxicology (2026) Specialty Sections of SOT. His major research interests include basic mechanisms and translational aspects of xenobiotic-induced hepatotoxicity and tissue repair, with a focus on acetaminophen overdose.

Dept. of Environmental Health Sciences, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA;Dept. of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA;Dept. of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA;Dr. McGill earned his undergraduate degree in biology from the University of Missouri-Kansas City, followed by his PhD in toxicology at the University of Kansas Medical Center (KUMC). At KUMC, his research focused on translating the mechanisms of acetaminophen (APAP) hepatotoxicity from animal models to humans using samples from APAP overdose patients. This ignited an interest in blood biomarkers that caused him to pursue formal training in clinical chemistry. After completing a fellowship in clinical chemistry and toxicology at Washington University School of Medicine in St. Louis, MO, he was recruited as faculty to the University of Arkansas for Medical Sciences in Little Rock, AR. Today, he is both a researcher and a practicing clinical chemist there. His independent laboratory studies both the fundamental mechanisms of drug-induced liver injury (DILI) as well as biomarkers of DILI for clinical and regulatory applications, while his clinical service is focused on biomarkers of toxicity as well as clinical pathology more generally.

Queen’s Medical Research Institute, University of Edinburgh, UK;Professor James Dear is a Clinical Pharmacologist at the University of Edinburgh and a Consultant for the National Poisons Information Service. His overall objective is to make medicines safer for patients. He focuses specifically on developing novel point-of-care biomarkers for drug toxicity, which has great importance to both clinical patient care and commercial drug development. Paracetamol overdose is the leading cause of acute liver failure in the Western world. Professor Dear is developing novel treatments for those patients at high risk of liver failure, a group without effective treatments. This includes leading multi-centre trials of new first-in-class therapeutics and Advanced Therapies, such as cell therapy, to repair the injured liver.

Department of Medicine and Dermatology, School of Medicine. University of Málaga, Malaga, Spain ;Raúl J. Andrade is Professor of Medicine at the University of Malaga and Director of the Gastroenterology Service, University Hospital of Málaga. Professor Andrade is the Director of the Spanish Drug Induced Liver Injury (DILI) Registry network and the Spanish Latin-American DILI Network. He was also responsible for setting up the Prospective European DILI Registry, which is funded by the European Association for the Study of the Liver. Professor Andrade has been involved in the development of a number of guidelines and is a member of a number of working groups and expert panels (including the Hepatotoxicity Special Interest group sponsored by the American Association for the Study of Liver Diseases and the CIOMS DILI working group sponsored by the World Health Organization and the Unesco). He has also acted as an Expert for the World Health Organization, the European Medicines Agency (EMA) and the Spanish Medicines Agency in the evaluation of liver safety of drugs. .He has published over 400 peer-reviewed articles in addition to 43 book chapters. Finally, he has undertaken over 300 presentations at national and international congresses, presenting on liver-related topics.